HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients Sample, Treatment, and Monitoring
2.2. Statistical Analysis
3. Results
3.1. Patients’ Features
3.2. Predictive Values of Clinical Parameters
3.3. Immune-Related Pneumonitis by a Centralized Radiological Board Review
3.4. Laboratory Analysis and HLA Typing
3.5. Statistical Correlation
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Horn, L.; Spigel, D.R.; Vokes, E.E.; Holgado, E.; Ready, N.; Steins, M.; Poddubskaya, E.; Borghaei, H.; Felip, E.; Paz-Ares, L.; et al. Nivolumab versus docetaxel in previously treated patients with advanced Non-Small-Cell lung cancer: Two-Year outcomes from two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 2017, 35, 3924–3933. [Google Scholar] [CrossRef] [PubMed]
- Xia, L.; Liu, Y.; Wang, Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 2019, 24, S31–S41. [Google Scholar] [CrossRef] [Green Version]
- Day, D.; Hansen, A.R. Immune-Related adverse events associated with immune checkpoint inhibitors. BioDrugs 2016, 30, 571–584. [Google Scholar] [CrossRef] [PubMed]
- Weber, J.S.; Yang, J.C.; Atkins, M.B.; Disis, M.L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 2015, 33, 2092–2099. [Google Scholar] [CrossRef]
- Topalian, S.L.; Taube, J.M.; Anders, R.A.; Pardoll, D.M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 2016, 16, 275–287. [Google Scholar] [CrossRef]
- Nishino, M.; Giobbie-Hurder, A.; Hatabu, H.; Ramaiya, N.H.; Hodi, F.S. Incidence of programmed Cell Death 1 Inhibitor-Related pneumonitis in patients with advanced cancer: A systematic review and Meta-analysis. JAMA Oncol. 2016, 2, 1607–1616. [Google Scholar] [CrossRef] [Green Version]
- Naidoo, J.; Wang, X.; Woo, K.M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J.E.; Segal, N.H.; Callahan, M.K.; Lesokhin, A.M.; et al. Pneumonitis in patients treated with anti-programmed Death-1/Programmed death Ligand 1 Therapy. J. Clin. Oncol. 2017, 35, 709–717. [Google Scholar] [CrossRef] [Green Version]
- Chuzi, S.; Tavora, F.; Cruz, M.; Costa, R.; Chae, Y.K.; Carneiro, B.A.; Giles, F.J. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag. Res. 2017, 9, 207–213. [Google Scholar] [CrossRef] [Green Version]
- Bashey, A.; Medina, B.; Corringham, S.; Pasek, M.; Carrier, E.; Vrooman, L.; Lowy, I.; Solomon, S.R.; Morris, L.E.; Holland, H.K.; et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113, 1581–1588. [Google Scholar] [CrossRef]
- Friedman, C.F.; Proverbs-Singh, T.A.; Postow, M.A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol. 2016, 2, 1346–1353. [Google Scholar] [CrossRef] [PubMed]
- Tirumani, S.H.; Ramaiya, N.H.; Keraliya, A.; Bailey, N.D.; Ott, P.A.; Hodi, F.S.; Nishino, M. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol. Res. 2015, 3, 1185–1192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Danlos, F.X.; Pages, C.; Baroudjian, B.; Vercellino, L.; Battistella, M.; Mimoun, M.; Jebali, M.; Bagot, M.; Tazi, A.; Lebbe, C. Nivolumab-Induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest 2016, 149, e133–e136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litiere, S.; Dancey, J.; Chen, A.; et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18, e143–e152. [Google Scholar] [CrossRef] [Green Version]
- Giannicola, R.; D’Arrigo, G.; Botta, C.; Agostino, R.; Del Medico, P.; Falzea, A.C.; Barbieri, V.; Staropoli, N.; Del Giudice, T.; Pastina, P.; et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. Mol. Clin. Oncol. 2019, 11, 81–90. [Google Scholar] [CrossRef]
- Simmonds, M.J.; Gough, S.C. Genetic insights into disease mechanisms of autoimmunity. Br. Med. Bull. 2004, 71, 93–113. [Google Scholar] [CrossRef] [Green Version]
- Guasp, P.; Lorente, E.; Martin-Esteban, A.; Barnea, E.; Romania, P.; Fruci, D.; Kuiper, J.J.W.; Admon, A.; Lopez de Castro, J.A. Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet’s Disease-associated HLA-B*51 Peptidome. Mol. Cell Proteom. 2019, 18, 1491–1510. [Google Scholar] [CrossRef] [Green Version]
- Correale, P.; Cerretani, D.; Remondo, C.; Martellucci, I.; Marsili, S.; La Placa, M.; Sciandivasci, A.; Paolelli, L.; Pascucci, A.; Rossi, M.; et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol. Rep. 2006, 16, 133–140. [Google Scholar] [CrossRef]
- Correale, P.; Remondo, C.; Carbone, S.F.; Ricci, V.; Migali, C.; Martellucci, I.; Licchetta, A.; Addeo, R.; Volterrani, L.; Gotti, G.; et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol. 2010, 9, 685–693. [Google Scholar] [CrossRef] [Green Version]
- Correale, P.; Botta, C.; Basile, A.; Pagliuchi, M.; Licchetta, A.; Martellucci, I.; Bestoso, E.; Apollinari, S.; Addeo, R.; Misso, G.; et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol. 2011, 12, 112–118. [Google Scholar] [CrossRef] [Green Version]
- Pastina, P.; Nardone, V.; Croci, S.; Battaglia, G.; Vanni, F.; Bellan, C.; Barbarino, M.; Ricci, V.; Costantini, S.; Capone, F.; et al. Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. J. Thorac. Dis. 2017, 9, 3123–3131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martino, E.C.; Misso, G.; Pastina, P.; Costantini, S.; Vanni, F.; Gandolfo, C.; Botta, C.; Capone, F.; Lombardi, A.; Pirtoli, L.; et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2016, 2, 16025. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pastina, P.; Nardone, V.; Botta, C.; Croci, S.; Tini, P.; Battaglia, G.; Ricci, V.; Cusi, M.G.; Gandolfo, C.; Misso, G.; et al. Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). Oncotarget 2017, 8, 75904–75913. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Correale, P.; Cusi, M.G.; Del Vecchio, M.T.; Aquino, A.; Prete, S.P.; Tsang, K.Y.; Micheli, L.; Nencini, C.; La Placa, M.; Montagnani, F.; et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J. Immunol. 2005, 175, 820–828. [Google Scholar] [PubMed] [Green Version]
- Correale, P.; Botta, C.; Cusi, M.G.; Del Vecchio, M.T.; De Santi, M.M.; Gori Savellini, G.; Bestoso, E.; Apollinari, S.; Mannucci, S.; Marra, M.; et al. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int. J. Cancer 2012, 130, 1577–1589. [Google Scholar] [CrossRef] [PubMed]
- Caraglia, M.; Marra, M.; Budillon, A.; Meo, G.; Ricciardiello, F.; Bismuto, E.; Brachelente, G.; Francini, G.; Giordano, A.; Correale, P.; et al. Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Cancer Biol. Ther. 2005, 4, 1159–1167. [Google Scholar] [CrossRef] [Green Version]
- Correale, P.; Saladino, R.E.; Giannarelli, D.; Giannicola, R.; Agostino, R.; Staropoli, N.; Strangio, A.; Del Giudice, T.; Nardone, V.; Altomonte, M.; et al. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. J. Immunother. Cancer 2020, 8, e000733. [Google Scholar] [CrossRef]
- Chowell, D.; Morris, L.G.T.; Grigg, C.M.; Weber, J.K.; Samstein, R.M.; Makarov, V.; Kuo, F.; Kendall, S.M.; Requena, D.; Riaz, N.; et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018, 359, 582–587. [Google Scholar] [CrossRef] [Green Version]
- Correale, P.; Saladino, R.E.; Nardone, V.; Giannicola, R.; Agostino, R.; Pirtoli, L.; Caraglia, M.; Botta, C.; Tagliaferri, P. Could PD-1/PDL1 immune checkpoints be linked to HLA signature? Immunotherapy 2019, 11, 1523–1526. [Google Scholar] [CrossRef]
- Bjorkman, P.J.; Parham, P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu. Rev. Biochem. 1990, 59, 253–288. [Google Scholar] [CrossRef]
- Hudson, L.E.; Allen, R.L. Leukocyte Ig-Like receptors—A model for MHC class I disease associations. Front Immunol. 2016, 7, 281. [Google Scholar] [CrossRef]
- Gross, G.; Margalit, A. Targeting tumor-associated antigens to the MHC class I presentation pathway. Endocr. Metab. Immune Disord Drug Targets 2007, 7, 99–109. [Google Scholar] [CrossRef] [PubMed]
- Falk, K.; Rotzschke, O.; Stevanovic, S.; Jung, G.; Rammensee, H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991, 351, 290–296. [Google Scholar] [CrossRef] [PubMed]
- Leddon, S.A.; Sant, A.J. Generation of MHC class II-peptide ligands for CD4 T-cell allorecognition of MHC class II molecules. Curr. Opin Organ Transpl. 2010, 15, 505–511. [Google Scholar] [CrossRef] [PubMed]
- Trowsdale, J.; Knight, J.C. Major histocompatibility complex genomics and human disease. Annu. Rev. Genom. Hum. Genet 2013, 14, 301–323. [Google Scholar] [CrossRef] [Green Version]
- Palikhe, A.; Lokki, M.L.; Saikku, P.; Leinonen, M.; Paldanius, M.; Seppanen, M.; Valtonen, V.; Nieminen, M.S.; Sinisalo, J. Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease. Clin. Vaccine Immunol. 2008, 15, 55–59. [Google Scholar] [CrossRef] [Green Version]
- Lenna, S.; Townsend, D.M.; Tan, F.K.; Kapanadze, B.; Markiewicz, M.; Trojanowska, M.; Scorza, R. HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells. J. Immunol. 2010, 184, 4654–4661. [Google Scholar] [CrossRef] [Green Version]
- Parker, B.; Urowitz, M.B.; Gladman, D.D.; Lunt, M.; Donn, R.; Bae, S.C.; Sanchez-Guerrero, J.; Romero-Diaz, J.; Gordon, C.; Wallace, D.J.; et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort. Ann. Rheum Dis. 2015, 74, 1530–1536. [Google Scholar] [CrossRef]
- Silva, J.M.F.; Ladomenou, F.; Carpenter, B.; Chandra, S.; Sedlacek, P.; Formankova, R.; Grandage, V.; Friswell, M.; Cant, A.J.; Nademi, Z.; et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2018, 2, 777–786. [Google Scholar] [CrossRef] [Green Version]
- Kuwana, M.; Kaburaki, J.; Arnett, F.C.; Howard, R.F.; Medsger, T.A., Jr.; Wright, T.M. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum. 1999, 42, 465–474. [Google Scholar] [CrossRef]
- Thio, C.L.; Carrington, M.; Marti, D.; O’Brien, S.J.; Vlahov, D.; Nelson, K.E.; Astemborski, J.; Thomas, D.L. Class II HLA alleles and hepatitis B virus persistence in African Americans. J. Infect Dis. 1999, 179, 1004–1006. [Google Scholar] [CrossRef]
- Madeleine, M.M.; Brumback, B.; Cushing-Haugen, K.L.; Schwartz, S.M.; Daling, J.R.; Smith, A.G.; Nelson, J.L.; Porter, P.; Shera, K.A.; McDougall, J.K.; et al. Human leukocyte antigen class II and cervical cancer risk: A population-based study. J. Infect Dis. 2002, 186, 1565–1574. [Google Scholar] [CrossRef] [PubMed]
- Attia, P.; Phan, G.Q.; Maker, A.V.; Robinson, M.R.; Quezado, M.M.; Yang, J.C.; Sherry, R.M.; Topalian, S.L.; Kammula, U.S.; Royal, R.E.; et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23, 6043–6053. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, W.; Green, M.; Liu, J.R.; Lawrence, T.S.; Zou, W. CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. In Oncoimmunology: A Practical Guide for Cancer Immunotherapy, 1st ed.; Zitvogel, L., Kroemer, G., Eds.; Springer International Publishing: Cham, Switzerland, 2018; pp. 23–39. [Google Scholar]
- Ackermann, C.J.; Reck, M.; Paz-Ares, L.; Barlesi, F.; Califano, R. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. Lung Cancer 2019, 134, 245–253. [Google Scholar] [CrossRef] [PubMed]
- Mulkey, F.; By, K.; Theoret, M.R.; Maher, V.E.; Padzur, R.; Sridhara, R. Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA). ASCO Annual Meeting, Chicago. J. Clin Oncol. 2019, 37, 2516. [Google Scholar] [CrossRef]
Hystology | Number of Patients | Sex | RT | TKI | First-Line Treatment Prior ICIs |
---|---|---|---|---|---|
SqNSCLC | 62 | M: 55; F: 7 | Y: 27; N: 35 | Y: 10; N: 52 | None: 2 Standard doublet: 41 mPE/mPEBev: 18 |
NsqNSCLC | 127 | M: 97; F: 30 | Y: 65; N: 62 | Y: 20; N: 105 | None: 16 Standard doublet: 60 mPE/mPEBev: 49 |
Other | 67 | M: 42; F: 25 | Y: 16; N: 38; NA: 13 | NA | NA |
Hystology | Atezo | IRP | Pembro | IRP | Nivo | IRP | Overall IRP | Overall irAEs |
---|---|---|---|---|---|---|---|---|
SqNSCLC | 10 | S: 0 NS: 1 | 1 | S: 0 NS: 0 | 51 | S: 3 NS: 2 | S: 3 (4.8%) NS: 3 (4.8%) S+NS: 6 (9.7%) | 18 (29%) |
NsqNSCLC | 21 | S: 2 NS: 0 | 19 | S: 0 NS:2 | 87 | S: 9 NS: 5 | S: 11 (8.7%) NS: 7 (5.5%) S+NS: 18 (14.2%) | 45 (35.4%) |
Melanoma | 0 | S: 0 NS: 0 | 3 | S: 0 NS: 0 | 16 | S: 0 NS: 2 | S: 0 (−) NS: 2 (10.5%) | 2 (10.5%) |
Miscellaneous | 7 | S: 0 NS: 0 | 6 | S: 0 NS: 0 | 35 | S: 0 NS:3 | S: 0 (−) NS: 3 (7.5%) | 3 (7.5%) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Correale, P.; Saladino, R.E.; Giannarelli, D.; Sergi, A.; Mazzei, M.A.; Bianco, G.; Giannicola, R.; Iuliano, E.; Forte, I.M.; Calandruccio, N.D.; et al. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. Cells 2020, 9, 1964. https://doi.org/10.3390/cells9091964
Correale P, Saladino RE, Giannarelli D, Sergi A, Mazzei MA, Bianco G, Giannicola R, Iuliano E, Forte IM, Calandruccio ND, et al. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. Cells. 2020; 9(9):1964. https://doi.org/10.3390/cells9091964
Chicago/Turabian StyleCorreale, Pierpaolo, Rita Emilena Saladino, Diana Giannarelli, Andrea Sergi, Maria Antonietta Mazzei, Giovanna Bianco, Rocco Giannicola, Eleonora Iuliano, Iris Maria Forte, Natale Daniele Calandruccio, and et al. 2020. "HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis" Cells 9, no. 9: 1964. https://doi.org/10.3390/cells9091964